Antiplatelet Therapy in Coronary Heart Disease Prevention

Cardiology Clinics

Volumn 29, Issue 1, 2011, Pages 71-85

  Kolandaivelu, Kumaran ^a,b   Bhatt, Deepak L ^a,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiplatelet; Cardiovascular; Coronary; Prevention

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; E 5555; ELINOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; ELDERLY CARE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SOCIOECONOMICS; STENT THROMBOSIS; WOMEN'S HEALTH;

CORONARY DISEASE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 78751616421     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.10.001     Document Type: Review

References (77)

1. Davi G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007, 357(24):2482-2494.
2. Michelson A.D. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010, 9(2):154-169.
3. Desai N.R., Bhatt D.L. The state of periprocedural antiplatelet therapy after recent trials. JACC Cardiovasc Interv 2010, 3(6):571-583.
4. Patrono C., Baigent C., Hirsh J., et al. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(Suppl 6):199S-233S.
5. Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003, 2(1):15-28.
6. Nagarakanti R., Sodhi S., Lee R., et al. Chronic antithrombotic therapy in post-myocardial infarction patients. Cardiol Clin 2008, 26(2):277-288. vii.
7. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121(7):e46-e215.
8. Bhatt D.L. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med 2007, 357(20):2078-2081.
9. Patrono C., Garcia Rodriguez L.A., Landolfi R., et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005, 353(22):2373-2383.
10. Patrono C., Rocca B. The future of antiplatelet therapy in cardiovascular disease. Annu Rev Med 2010, 61:49-61.
11. Sanmuganathan P.S., Ghahramani P., Jackson P.R., et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001, 85(3):265-271.
12. Calonge N., Petitti D.B., DeWitt T.G., et al. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 150(6):396-404.
13. Sakhuja R., Yeh R.W., Bhatt D.L. Antiplatelet agents in acute coronary syndromes. Curr Probl Cardiol 2010, 35(3):123-170.
14. Campbell C.L., Smyth S., Montalescot G., et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007, 297(18):2018-2024.
15. Baigent C., Sudlow C., Collins R., et al. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324(7329):71-86.
16. Baigent C., Blackwell L., Collins R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373(9678):1849-1860.
17. Kolandaivelu K., Bhatt D.L. Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol 2010, 7(8):461-467.
18. Smith S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113(19):2363-2372.
19. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360(4):354-362.
20. von Beckerath N., Taubert D., Pogatsa-Murray G., et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 2005, 112(19):2946-2950.
21. CAPRIESteeringCommittee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348(9038):1329-1339.
22. Gaspoz J.M., Coxson P.G., Goldman P.A., et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002, 346(23):1800-1806.
23. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345(7):494-502.
24. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358(9281):527-533.
25. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354(16):1706-1717.
26. Bhatt D.L., Flather M.D., Hacke W., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007, 49(19):1982-1988.
27. Berger P.B., Bhatt D.L., Fuster V., et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010, 121(23):2575-2583.
28. Menon B.K., Frankel M.R., Liang L., et al. Rapid change in prescribing behavior in hospitals participating in Get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. Stroke 2010, 41(9):2094-2097.
29. Windecker S., Meier B. Late coronary stent thrombosis. Circulation 2007, 116(17):1952-1965.
30. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005, 45(2):246-251.
31. Sweeny J.M., Gorog D.A., Fuster V. Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009, 6(4):273-282.
32. Shuldiner A.R., O'Connell J.R., Bliden K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302(8):849-857.
33. Sibbing D., Koch W., Gebhard D., et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010, 121(4):512-518.
34. Juurlink D.N. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation 2009, 120(23):2310-2312.
35. Mehta S.R., Bassand J.P., Chrolavicius S., et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010, 363(10):930-942.
36. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007, 116(25):2923-2932.
37. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357(20):2001-2015.
38. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361(11):1045-1057.
39. Bhatt D.L. Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?. Nat Rev Cardiol 2009, 6(12):737-738.
40. Bhatt D.L., Lincoff A.M., Gibson C.M., et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009, 361(24):2330-2341.
41. Harrington R.A., Stone G.W., McNulty S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009, 361(24):2318-2329.
42. Steinhubl S.R., Oh J.J., Oestreich J.H., et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008, 121(4):527-534.
43. Chew D.P., Bhatt D.L., Sapp S., et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001, 103(2):201-206.
44. De Schryver E.L., Algra A., van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2006, (2). CD001820.
45. Halkes P.H., van Gijn J., Kappelle L.J., et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006, 367(9523):1665-1673.
46. Sacco R.L., Diener H.C., Yusuf S., et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008, 359(12):1238-1251.
47. Croce K. Antiplatelet therapy after percutaneous coronary intervention: should another regimen be "TAPT?" Circ Cardiovasc Interv 2010, 3(1):3-5.
48. Cheng J.W. Cilostazol. Heart Dis 1999, 1(3):182-186.
49. Dauerman H.L., Bhatt D.L., Gretler D.D., et al. Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. Am Heart J 2010, 159(4):508-517. e501.
50. Nelson M.R., Reid C.M., Ames D.A., et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008, 189(2):105-109.
51. Melloni C., Berger J.S., Wang T.Y., et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010, 3(2):135-142.
52. Mosca L., Banka C.L., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007, 115(11):1481-1501.
53. Pearson T.A., Blair S.N., Daniels S.R., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002, 106(3):388-391.
54. Berger J.S., Bhatt D.L., Cannon C.P., et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol 2009, 54(21):1935-1945.
55. Pignone M., Alberts M.J., Colwell J.A., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010, 55(25):2878-2886.
56. Wiviott S.D., Braunwald E., Angiolillo D.J., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38. Circulation 2008, 118(16):1626-1636.
57. Angiolillo DJ. Antiplatelet therapy: new data on prasugrel from AHA 2009 - OPTIMUS-3 and SWAP trials. Paper presented at: AHA 2009. Orlando (FL), November 16, 2009.
58. Connolly S.J., Pogue J., Hart R.G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360(20):2066-2078.
59. Khurram Z., Chou E., Minutello R., et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006, 18(4):162-164.
60. Depta J.P., Cannon C.P., Fonarow G.C., et al. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol 2009, 104(9):1171-1178.
61. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008, 52(18):1502-1517.
62. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151.
63. Konstam M.A. Antithrombotic therapy in heart failure: WATCHful wondering. Circulation 2009, 119(12):1559-1561.
64. Gaziano T.A. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005, 112(23):3547-3553.
65. Mendis S., Abegunde D., Yusuf S., et al. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ 2005, 83(11):820-829.
66. Yusuf S., Pais P., Afzal R., et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009, 373(9672):1341-1351.
67. Bhatt D.L. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?. JAMA 2009, 302(8):896-897.
68. Breet N.J., van Werkum J.W., Bouman H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010, 303(8):754-762.
69. Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008, 51(14):1404-1411.
70. Bhatt D.L., Steg P.G., Ohman E.M., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006, 295(2):180-189.
71. Mehta R.H., Roe M.T., Chen A.Y., et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med 2006, 166(18):2027-2034.
72. Ho P.M., Spertus J.A., Masoudi F.A., et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006, 166(17):1842-1847.
73. Ho P.M., Peterson E.D., Wang L., et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008, 299(5):532-539.
74. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006, 113(24):2803-2809.
75. Ho P.M., Tsai T.T., Maddox T.M., et al. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care. Circ Cardiovasc Qual Outcomes 2010, 3(3):261-266.
76. Belch J., MacCuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008, 337:a1840.
77. Serebruany V.L., Atar D. Assessment of bleeding events in clinical trials-proposal of a new classification. Am J Cardiol 2007, 99(2):288-290.